Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSH | P09668 | 1/20 | 0.46 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693090 | 0.94 | CSNK1E (0.56) | CSNK1ESIGMAR1TAAR1SLC6A2MAOA | |
| SCHEMBL16752540 | 0.92 | CSNK1E (0.58) | CSNK1ESIGMAR1TAAR1SLC6A2MAOA | |
| SCHEMBL16752543 | 0.92 | CSNK1E (0.58) | CSNK1ESIGMAR1TAAR1SLC6A2MAOA | |
| SCHEMBL16752541 | 0.92 | CSNK1E (0.58) | CSNK1ESIGMAR1TAAR1SLC6A2MAOA | |
| SCHEMBL25212657 | 0.92 | CSNK1E (0.58) | CSNK1ESIGMAR1TAAR1SLC6A2MAOA | |
| SCHEMBL25204172 | 0.92 | CSNK1E (0.58) | CSNK1ESIGMAR1TAAR1SLC6A2MAOA | |
| SCHEMBL9242565 | 0.92 | CSNK1E (0.58) | CSNK1ESIGMAR1TAAR1SLC6A2MAOA | |
| SCHEMBL16370367 | 0.92 | CSNK1E (0.58) | CSNK1ESIGMAR1TAAR1SLC6A2MAOA | |
| SCHEMBL6060574 | 0.92 | CSNK1E (0.58) | CSNK1ESIGMAR1TAAR1SLC6A2MAOA | |
| SCHEMBL5678132 | 0.92 | CSNK1E (0.58) | CSNK1ESIGMAR1TAAR1SLC6A2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111727215-B | Antioxidant-containing methane-forming crosslinking composition and articles thereof | 博里利斯股份公司 | 2022-08-09 | — | — | CN | disclosed |
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| CN-108368296-B | High transparency melt polymerized polycarbonate with improved impact properties | 沙特基础工业全球技术公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-110746341-A | Method for purifying 2-aryl-3, 3-bis (4-hydroxyaryl) phthalimidines and polymers derived therefrom | 沙特基础工业全球技术有限公司 | 2020-02-04 | — | — | CN | disclosed |
| EP-3131965-A1 | METHODS OF PREPARING COMPOSITIONS FOR CONTAINERS AND OTHER ARTICLES AND METHODS OF USING SAME | Valspar Sourcing, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
| CN-106063946-A | Absorbability oxidized cellulose thromboembolism forms solution | 柯惠LP公司 | 2016-11-02 | — | — | CN | disclosed |
| EP-3019200-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015160788-A1 | METHODS OF PREPARING COMPOSITIONS FOR CONTAINERS AND OTHER ARTICLES AND METHODS OF USING SAME | VALSPAR SOURCING, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-2882818-A1 | STABILIZER AND COATING COMPOSITIONS THEREOF | Valspar Sourcing, Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014025411-A1 | CONTAINER COATING SYSTEM | VALSPAR SOURCING, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014025410-A1 | STABILIZER AND COATING COMPOSITIONS THEREOF | VALSPAR SOURCING, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014025406-A1 | DENTAL MATERIALS AND METHOD OF MANUFACTURE | VALSPAR SOURCING, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014025400-A1 | DEVELOPER FOR THERMALLY RESPONSIVE RECORD MATERIALS | VALSPAR SOURCING, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| EP-1379602-A1 | PROCESS FOR THE MANUFACTURE OF TEMPERATURE-SENSITIVE POLYMERS | Solutia Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002083812-A1 | PROCESS FOR THE MANUFACTURE OF TEMPERATURE-SENSITIVE POLYMERS | SOLUTIA INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-4351945-A | Two-phase process for the preparation of azole and azoline disulfides | EXXON RESEARCH & ENGINEERING CO. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4155910-A | OXIDATIVE COUPLING | EXXON RESEARCH & ENGINEERING CO. (US) | 1979-05-22 | — | — | US | disclosed |
| US-4064139-A | TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS, ANTI-PARKINSON'S DISEASE | MERCK & CO., INC. (US) | 1977-12-20 | — | — | US | disclosed |
| US-4039552-A | CORROSION INHIBITION, WEAR RESISTANCE | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | CSNK1E 3973/4885SIGMAR1 4432/4885TAAR1 2713/4885 |
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | RTCB, IGF2BP2, SNRPE | CSNK1E 2323/4885SIGMAR1 1320/4885TAAR1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.